Coley Pharmaceutical Group, Inc. (COLY) [Rocket]

In millions, except per share items	Dec-31-06	Dec-31-05	Dec-31-04	Dec-31-03	Dec-31-02
	10-K	10-K	10-K	10-K	S-1/A
Revenues:
United States	20.0	15.8	14.0	6.5
Canada	0.2	0.1	0.4	0.1
Total revenues	20.2	15.9	14.3	6.5	14.2
Revenue growth [+]	27.2%	10.7%	119.1%	-53.9%
United States	27.2%	12.7%	115.4%
Canada	25.8%	-64.3%	541.1%
Cost of goods sold	14.4	13.2	8.6	9.2	12.0
Gross profit	5.8	2.7	5.7	-2.6	2.2
Gross margin	28.7%	16.9%	40.0%	-39.9%	15.5%
Selling, general and administrative [+]	12.3	11.8	7.7	8.6	10.9
General and administrative	12.3	11.8	7.7	8.6	10.9
Other operating expenses	28.6	31.3	31.5	19.6	11.6
EBITDA [+]	-33.5	-38.7	-31.5	-28.8	-18.9
EBITDA growth	-13.3%	22.8%	9.1%	52.4%
EBITDA margin	-166.0%	-243.4%	-219.4%	-440.4%	-133.3%
Depreciation	1.5	1.7	2.0	1.9	1.1
EBITA	-35.1	-40.4	-33.5	-30.7	-20.1
EBITA margin	-173.5%	-254.1%	-233.4%	-468.8%	-141.4%
Amortization of intangibles				0.2	0.2
EBIT [+]	-35.1	-40.4	-33.5	-30.9	-20.2
EBIT growth	-13.1%	20.5%	8.5%	52.5%
EBIT margin	-173.5%	-254.1%	-233.4%	-471.3%	-142.5%
Interest income, net [+]	5.5	2.2	-0.4	-0.8	0.1
Interest expense	0.3	0.5	0.7	1.1	0.4
Interest income	5.8	2.7	0.3	0.3	0.6
Other income (expense), net	-0.1	-0.1	0.0	1.2	0.0
Pre-tax income	-29.6	-38.2	-33.9	-30.5	-20.2
Income taxes	0.1	-0.2	0.1	0.0	-0.2
Tax rate		0.4%			0.8%
Net income	0.0	0.0	0.0	-16.1	-26.4
Net margin	-0.1%	-0.3%	-0.3%	-246.5%	-185.9%

Basic EPS [+]	($1.13)	($3.68)	($37.31)	($16.20)	($26.44)
Growth	-69.3%	-90.1%	130.3%	-38.7%
Diluted EPS [+]	($1.13)	($3.68)	($37.31)	($16.20)	($26.44)
Growth	-69.3%	-90.1%	130.3%	-38.7%

Shares outstanding (basic) [+]	0.0	0.0	0.0	1.0	1.0
Growth	142.1%	993.2%	-99.9%	-0.2%
Shares outstanding (diluted) [+]	0.0	0.0	0.0	1.0	1.0
Growth	142.1%	993.2%	-99.9%	-0.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.